PEARQ — Pear Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- -$31.82m
- $12.69m
Annual income statement for Pear Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 32.6 | 9.38 | 4.21 | 12.7 |
| Cost of Revenue | ||||
| Gross Profit | 31.6 | 7.67 | -1.02 | 5.3 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 43.9 | 87 | 110 | 136 |
| Operating Profit | -11.3 | -77.6 | -106 | -123 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -9.33 | -97 | -65.1 | -75.5 |
| Net Income After Taxes | -9.33 | -97 | -65.1 | -75.5 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -9.33 | -97 | -65.1 | -75.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -9.33 | -97 | -65.1 | -75.5 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.215 | -0.697 | -0.575 | -0.5 |